322338
Dvl-PDZ Domain Inhibitor II
The Dvl-PDZ Domain Inhibitor II, also referenced under CAS 294891-81-9, controls the biological activity of Dvl-PDZ. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.
别名:
Dvl-PDZ Domain Inhibitor II, Wnt Pathway Inhibitor IV, 2-((3-(2-Phenylacetyl)amino)benzoyl)amino)benzoic acid, 3289-8625
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H18N2O4
化学文摘社编号:
分子量:
374.39
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.28
SMILES string
N(c2cc(ccc2)C(=O)Nc3c(cccc3)C(=O)O)C(=O)Cc1ccccc1
InChI
1S/C22H18N2O4/c25-20(13-15-7-2-1-3-8-15)23-17-10-6-9-16(14-17)21(26)24-19-12-5-4-11-18(19)22(27)28/h1-12,14H,13H2,(H,23,25)(H,24,26)(H,27,28)
InChI key
OBGIRQUECFHUEY-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
white
solubility
DMSO: 50 mg/mL
shipped in
ambient
Quality Level
General description
A cell-permeable amidobenzanilide compound that disrupts Fz-Dvl (frizzled-dishevelled) interaction by targeting the PDZ domain (Kd = 10.6 µM) of Dvl, blocking Wnt3a-induced (10 ng/ml) transcription activity (~50% inhibition at 3 µM in 293 cell SuperTopflash reporter assays) and suppressing the Wnt pathway-dependent growth of prostate cancer PC-3 cells (by 16% in 72 h at ≥50 µM; IC50 = 12.5 µM). Shown to effectively prevent Wnt3A mRNA injection-induced xenopus embryo deformation (effective conc. = 25 µM) and suppress Wnt pathway-mediated apoptosis of the hyaloid vescular endothelial cells in the mouse eyes via vitreous injection (144 fmol/120 nl/eye) in vivo.
Packaging
Packaged under inert gas
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Grandy, D., et al. 2009. J. Biol. Chem.284, 16256.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Yisong Xu et al.
Artificial cells, nanomedicine, and biotechnology, 46(sup2), 192-200 (2018-03-28)
Acquired resistance to 5-fluorouracil (5-FU) frequently occurs in patients with hepatocellular carcinoma (HCC), the underlying molecular mechanisms of which are poorly understood. The aim of this study was to identify candidate genes and associated signalling pathways that may play a
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持